Evaluación de melaza como medio de cultivo para la producción de bacterias ácido-lácticas

Bioprocesses are those processes that involve the manipulation of living organisms or their cellular components as substrates in order to obtain a biomass or product to provide goods or services as an example, the use of bacteria acid lactic acid in biopreservacion, this was proposed as target bacteria produce acid lactic acid in an aerobic bioreactor through a conventional molasses as carbon source and check the development of the micro-organism as biomass, to accomplish this was carried out in two different twinjet with volumes of 7, 5L, 0, 5 L using the same substrate and inoculum I, evaluating chemical variables such as pH, acidity, ºbrix, reducing sugars and absorbance . The results show a correct development of the bacteria metabolism lactic acid observing one acidification of the environment demonstrating in the pH decrease and increase of titrable acidity, also seeing a decrease in sugars reducers interpreting this as the consumption of the carbon of the micro-organism and the realization of a process source fermentation and verifying the biomass growth through units of absorbance and the weight of the produced biomass, and may conclude that there was a proper acid development of bacteria lactic demonstrating that molasses is a source of carbon and a half of crop suitable for the production of this bacterium.Los bioprocesos son aquellos procesos que involucran la manipulación de organismos vivos o sus componentes celulares como sustratos, con el fin de obtener una biomasa o producto para proveer bienes o servicios, por ejemplo, el uso de bacterias ácido lácticas en biopreservación, por esto se propuso como objetivo producir bacterias ácido lácticas en un biorreactor aerobio a través de una fuente de carbono convencional como la melaza y comprobar el desarrollo del microorganismo como biomasa, para realizar esto se realizó en dos diferentes birreactores con volúmenes de 7,5L y 0,5L utilizando el mismo sustrato e inóculo, evaluando variables químicas como lo son el pH, acidez, °Brix, azúcares reductores y absorbancia. Los resultados mostraron un correcto desarrollo del metabolismo de la bacteria ácido láctica observando una acidificación del medio evidenciándose en la disminución del pH y el aumento de la acidez titulable, mostrando también una disminución en los azúcares reductores; interpretando esto, como el consumo de la fuente de carbono del microorganismo y la realización de un proceso fermentativo y verificando un crecimiento de la biomasa a través de las unidades de absorbancia y el peso de la biomasa producida, concluyendo que hubo un correcto desarrollo de la bacteria ácido láctica, demostrando que la melaza es una fuente de carbono y medio de cultivo apto para la producción de esta bacteria

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

RICORS2040 : The need for collaborative research in chronic kidney disease

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true

Gestión efectiva de emprendimientos sociales: Lecciones extraídas de empresas y organizaciones de la sociedad civil en Iberoamérica

Este libro reúne los casos de 40 entidades de primera línea de América Latina y España, tanto empresas como organizaciones de la sociedad civil, comprometidas en acciones sociales originales, que la Social Enterprise Knowledge Network (SEKN, Red de Conocimientos sobre Emprendimientos Sociales) ha estudiado con todo detalle.